Abstract
Pathological Gambling (PG) is characterized by “the failure to resist gambling impulses despite severe personal, family or occupational consequences”. PG estimated prevalence ranges between 0.4% and 3.4% within the adult population. PG seems to be more common in patients with Parkinson’s disease (PD) than in the general population. In the past few years, PG has been reported as a side effect of dopamine agonist (DA) therapy used in PD. This association has aroused great interest for the dramatic impact PG has on patients’ quality of life. Management of PG in patients with PD could be demanding. It is based on patient and caregiver education, modification of dopamine replacement therapy, and in some cases psychoactive drug administration. This review describes possible pathogenesis of PG associated with DA therapy, available pharmacological treatments and management approaches that may increase the likelihood of satisfactory treatment outcomes in PD patients.
Keywords: Behavioural therapy, dopamine agonists, impulse control disorders, Parkinson’s disease, pathological gambling, pharmacological therapy, DA therapy, dopamine dysregulation syndrome, OC spectrum disorders, compulsive eating, Mood disorders , impulsivity, Non-ergot dopamine agonists, pharmacologic treatment, Parkinsonism
Current Psychopharmacology
Title:Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Volume: 1
Author(s): Domenico Pirritano, Massimiliano Plastino, Antonietta Fava, Dario Cristiano, Luca Gallelli, Carmela Colica and Domenico Bosco
Affiliation:
Keywords: Behavioural therapy, dopamine agonists, impulse control disorders, Parkinson’s disease, pathological gambling, pharmacological therapy, DA therapy, dopamine dysregulation syndrome, OC spectrum disorders, compulsive eating, Mood disorders , impulsivity, Non-ergot dopamine agonists, pharmacologic treatment, Parkinsonism
Abstract: Pathological Gambling (PG) is characterized by “the failure to resist gambling impulses despite severe personal, family or occupational consequences”. PG estimated prevalence ranges between 0.4% and 3.4% within the adult population. PG seems to be more common in patients with Parkinson’s disease (PD) than in the general population. In the past few years, PG has been reported as a side effect of dopamine agonist (DA) therapy used in PD. This association has aroused great interest for the dramatic impact PG has on patients’ quality of life. Management of PG in patients with PD could be demanding. It is based on patient and caregiver education, modification of dopamine replacement therapy, and in some cases psychoactive drug administration. This review describes possible pathogenesis of PG associated with DA therapy, available pharmacological treatments and management approaches that may increase the likelihood of satisfactory treatment outcomes in PD patients.
Export Options
About this article
Cite this article as:
Pirritano Domenico, Plastino Massimiliano, Fava Antonietta, Cristiano Dario, Gallelli Luca, Colica Carmela and Bosco Domenico, Pathological Gambling in Parkinson’s Disease: An Update on Medical Management, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040365
DOI https://dx.doi.org/10.2174/2211556011201040365 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Regulators of Intracellular Calcium Release Channels
Current Pharmaceutical Design Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Current Drug Metabolism Neuroimaging of Narcolepsy
CNS & Neurological Disorders - Drug Targets Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Maternal Exposure to Quetiapine: Effects on Structural Changes in Developing Brain and its Lasting Impact on Neurobehavioral Impairments in Rat Offspring
Current Psychopharmacology The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Molecular Chaperone Activity and Biological Regulatory Actions of the TPR-Domain Immunophilins FKBP51 and FKBP52
Current Protein & Peptide Science Linaclotide-a Novel Secretagogue in the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
Mini-Reviews in Medicinal Chemistry Beyond the Synapse and Hebb's Rule: Is the Rest of the Neuron More Important for Psychiatric Disorders?
Current Psychiatry Reviews Retromer Dysfunction and Neurodegenerative Disease
Current Genomics An fMRI Study of the Neural Systems Involved in Visually Cued Tactile Top-Down Spatial and Temporal Attention
Neuroscience and Biomedical Engineering (Discontinued) Current State of Development of Genome Analysis in Livestock
Current Genomics Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Arsenic-exposed Keratinocytes Exhibit Differential microRNAs Expression Profile; Potential Implication of miR-21, miR-200a and miR-141 in Melanoma Pathway
Clinical Cancer Drugs Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook
Current Medicinal Chemistry